NO331198B1 - Anvendelse av LHRH-antagonist for fremstilling av et medikament til terapeutisk styring av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte og egglederobstruksjon - Google Patents

Anvendelse av LHRH-antagonist for fremstilling av et medikament til terapeutisk styring av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte og egglederobstruksjon

Info

Publication number
NO331198B1
NO331198B1 NO20021430A NO20021430A NO331198B1 NO 331198 B1 NO331198 B1 NO 331198B1 NO 20021430 A NO20021430 A NO 20021430A NO 20021430 A NO20021430 A NO 20021430A NO 331198 B1 NO331198 B1 NO 331198B1
Authority
NO
Norway
Prior art keywords
drug
manufacture
fallopian tube
pelvic pain
chronic pelvic
Prior art date
Application number
NO20021430A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021430L (no
NO20021430D0 (no
Inventor
Juergen Engel
Hilde Riethmueller-Winzen
Klaus Diedrich
Ricardo Felberbaum
Wolfgang KUEPKER
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20021430D0 publication Critical patent/NO20021430D0/no
Publication of NO20021430L publication Critical patent/NO20021430L/no
Publication of NO331198B1 publication Critical patent/NO331198B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20021430A 1999-09-23 2002-03-21 Anvendelse av LHRH-antagonist for fremstilling av et medikament til terapeutisk styring av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte og egglederobstruksjon NO331198B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Publications (3)

Publication Number Publication Date
NO20021430D0 NO20021430D0 (no) 2002-03-21
NO20021430L NO20021430L (no) 2002-05-07
NO331198B1 true NO331198B1 (no) 2011-10-31

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021430A NO331198B1 (no) 1999-09-23 2002-03-21 Anvendelse av LHRH-antagonist for fremstilling av et medikament til terapeutisk styring av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte og egglederobstruksjon

Country Status (22)

Country Link
EP (1) EP1214086A2 (enExample)
JP (2) JP2003509467A (enExample)
KR (1) KR100772852B1 (enExample)
CN (2) CN101045155A (enExample)
AU (1) AU769482B2 (enExample)
BG (1) BG66128B1 (enExample)
BR (1) BR0014198A (enExample)
CA (1) CA2383510A1 (enExample)
HK (1) HK1049117A1 (enExample)
HU (1) HUP0202741A3 (enExample)
IL (1) IL148185A0 (enExample)
MX (1) MXPA02002436A (enExample)
NO (1) NO331198B1 (enExample)
NZ (1) NZ534836A (enExample)
PL (1) PL201898B1 (enExample)
RU (1) RU2255759C2 (enExample)
SK (1) SK3752002A3 (enExample)
TR (1) TR200200738T2 (enExample)
TW (1) TWI267373B (enExample)
UA (1) UA73956C2 (enExample)
WO (1) WO2001021194A2 (enExample)
ZA (1) ZA200201374B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
ES2633453T3 (es) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
MX2020001877A (es) 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
BR112020021276A2 (pt) 2018-04-19 2021-01-26 Abbvie Inc. métodos de tratamento de sangramento menstrual intenso
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
DE69515666T2 (de) * 1994-07-22 2000-07-06 Medical College Of Hampton Roads, Norfolk VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
EP0986550A1 (en) * 1997-06-05 2000-03-22 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
AU7779200A (en) 2001-04-24
EP1214086A2 (en) 2002-06-19
JP2003509467A (ja) 2003-03-11
HK1049117A1 (zh) 2003-05-02
CN101045155A (zh) 2007-10-03
AU769482B2 (en) 2004-01-29
HUP0202741A2 (hu) 2003-01-28
CN1376070A (zh) 2002-10-23
ZA200201374B (en) 2002-10-30
TWI267373B (en) 2006-12-01
MXPA02002436A (es) 2003-02-12
JP2012051920A (ja) 2012-03-15
KR20020035879A (ko) 2002-05-15
KR100772852B1 (ko) 2007-11-02
CA2383510A1 (en) 2001-03-29
IL148185A0 (en) 2002-09-12
PL201898B1 (pl) 2009-05-29
NO20021430L (no) 2002-05-07
PL353244A1 (en) 2003-11-03
BG66128B1 (bg) 2011-06-30
TR200200738T2 (tr) 2002-08-21
WO2001021194A3 (en) 2002-03-14
SK3752002A3 (en) 2003-06-03
WO2001021194A2 (en) 2001-03-29
BR0014198A (pt) 2002-05-21
HUP0202741A3 (en) 2003-12-29
NZ534836A (en) 2007-07-27
UA73956C2 (en) 2005-10-17
BG106584A (bg) 2003-02-28
RU2255759C2 (ru) 2005-07-10
NO20021430D0 (no) 2002-03-21

Similar Documents

Publication Publication Date Title
IL158306A0 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
DK1242055T3 (da) Hydrogelstyret doseringsform til lægemidler
IL150657A0 (en) Multi-step drug dosage forms
PL360658A1 (en) Hydrogel-driven drug dosage form
NO20015797L (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
ZA200306125B (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
GB0117618D0 (en) Pharmaceutical dosage form
HUP0401281A3 (en) Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals
NO20021400L (no) Terapeutiske kinazolinderivater
GB0117619D0 (en) Pharmaceutical dosage form
AU7528101A (en) A device for delivering a therapeutic dosage
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
NO331198B1 (no) Anvendelse av LHRH-antagonist for fremstilling av et medikament til terapeutisk styring av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte og egglederobstruksjon
NO20021094D0 (no) Profylaktiske og terapeutiske medikamenter for oftalmologiske sykdommer
IL159345A0 (en) Active ingredient combination for pharmacological addictive substances or intoxicant therapy
AU2001264920A1 (en) Therapeutic uses of il-1 receptor antagonist
IL151922A0 (en) Transdermal therapeutic system for the delivery of lerisetron
AU2001228656A1 (en) Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
AU2003220523A8 (en) Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
SI1390063T1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
HK1055686A (en) Therapeutic polyanhydride compounds for drug delivery
DK1897944T3 (da) IL-17 homologe polypeptider og terapeutisk anvendelse deraf
IL149853A0 (en) Gastroretentive controlled release pharmaceutical dosage forms
IL128582A0 (en) Pharmaceutical dosage form

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees